Cited 3 times in
A phase II study of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin (ESHAOx) for patients with refractory or relapsed Hodgkin's lymphoma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김진석 | - |
dc.contributor.author | 이혜원 | - |
dc.date.accessioned | 2022-09-06T06:37:43Z | - |
dc.date.available | 2022-09-06T06:37:43Z | - |
dc.date.issued | 2020-02 | - |
dc.identifier.issn | 0939-5555 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/190235 | - |
dc.description.abstract | We assessed the efficacy and toxicity of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin (ESHAOx) combination chemotherapy in patients with refractory or relapsed Hodgkin's lymphoma (HL). This was an open-label, non-randomized, multi-center phase II study. The ESHAOx regimen consisted of intravenous (i.v.) etoposide 40 mg/m(2) on days 1 to 4, i.v. methylprednisolone 500 mg on days 1 to 5, i.v. cytarabine 2 g/m(2) on day 5, and i.v. oxaliplatin 130 mg/m(2) on day 1. Cycles (up to six) were repeated every 3 weeks. In an effort to identify prognostic markers, the serum levels of cytokines including tumor necrosis factor-alpha (TNF-alpha), C-reactive protein (CRP), and vascular endothelial growth factor (VEGF) were measured at the time of study entry. A total of 37 patients were enrolled, and 36 were available for evaluation of tumor response. The overall response rate was 72.2% (26/36) (complete response, 33.3% [12/36]; partial response, 38.9% [14/36]). The median time to progression was 34.9 months (95% confidence interval, 23.1-46.7 months). The most common grade 3 or 4 hematological adverse events were neutropenia (16/37, 43.2%), followed by thrombocytopenia (10/37, 27.0%). Grade 3 or 4 non-hematological adverse events were nausea (3/37, 8.1%), anorexia (2/37, 5.4%), mucositis (1/37, 2.7%), and skin rash (1/37, 2.7%). There were no treatment-related deaths. High levels of TNF-alpha and CRP were significantly associated with poorer overall survival (p = 0.00005 for TNF-alpha, p = 0.0004 for CRP, respectively). The ESHAOx regimen exhibited antitumor activity and an acceptable safety profile in patients with refractory or relapsed HL. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Springer International | - |
dc.relation.isPartOf | ANNALS OF HEMATOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols / administration & dosage* | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols / adverse effects | - |
dc.subject.MESH | C-Reactive Protein / metabolism | - |
dc.subject.MESH | Cytarabine / administration & dosage | - |
dc.subject.MESH | Cytarabine / adverse effects | - |
dc.subject.MESH | Disease-Free Survival | - |
dc.subject.MESH | Etoposide / administration & dosage | - |
dc.subject.MESH | Etoposide / adverse effects | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Hodgkin Disease* / blood | - |
dc.subject.MESH | Hodgkin Disease* / drug therapy | - |
dc.subject.MESH | Hodgkin Disease* / mortality | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Methylprednisolone / administration & dosage | - |
dc.subject.MESH | Methylprednisolone / adverse effects | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Neoplasm Proteins / blood* | - |
dc.subject.MESH | Oxaliplatin / administration & dosage | - |
dc.subject.MESH | Oxaliplatin / adverse effects | - |
dc.subject.MESH | Recurrence | - |
dc.subject.MESH | Survival Rate | - |
dc.subject.MESH | Time Factors | - |
dc.subject.MESH | Tumor Necrosis Factor-alpha / blood | - |
dc.subject.MESH | Vascular Endothelial Growth Factor A / blood | - |
dc.title | A phase II study of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin (ESHAOx) for patients with refractory or relapsed Hodgkin's lymphoma | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Young-Woong Won | - |
dc.contributor.googleauthor | Hyewon Lee | - |
dc.contributor.googleauthor | Hyeon-Seok Eom | - |
dc.contributor.googleauthor | Jin Seok Kim | - |
dc.contributor.googleauthor | Cheolwon Suh | - |
dc.contributor.googleauthor | Dok Hyun Yoon | - |
dc.contributor.googleauthor | Jung Yong Hong | - |
dc.contributor.googleauthor | Hye Jin Kang | - |
dc.contributor.googleauthor | Jae Hoon Lee | - |
dc.contributor.googleauthor | Won Seog Kim | - |
dc.contributor.googleauthor | Seok Jin Kim | - |
dc.contributor.googleauthor | Won-Sik Lee | - |
dc.contributor.googleauthor | Myung Hee Chang | - |
dc.contributor.googleauthor | Young Rok Do | - |
dc.contributor.googleauthor | Jun Ho Yi | - |
dc.contributor.googleauthor | Inho Kim | - |
dc.contributor.googleauthor | Jong-Ho Won | - |
dc.contributor.googleauthor | Kyoungha Kim | - |
dc.contributor.googleauthor | Sung Yong Oh | - |
dc.contributor.googleauthor | Jae-Cheol Jo | - |
dc.identifier.doi | 10.1007/s00277-019-03891-9 | - |
dc.contributor.localId | A01017 | - |
dc.contributor.localId | A03318 | - |
dc.relation.journalcode | J00161 | - |
dc.identifier.eissn | 1432-0584 | - |
dc.identifier.pmid | 31897676 | - |
dc.identifier.url | https://link.springer.com/article/10.1007/s00277-019-03891-9 | - |
dc.subject.keyword | Etoposide | - |
dc.subject.keyword | Methylprednisolone | - |
dc.subject.keyword | Cytarabine | - |
dc.subject.keyword | Oxaliplatin | - |
dc.subject.keyword | Hodgkin's lymphoma | - |
dc.contributor.alternativeName | Kim, Jin Seok | - |
dc.contributor.affiliatedAuthor | 김진석 | - |
dc.contributor.affiliatedAuthor | 이혜원 | - |
dc.citation.volume | 99 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 255 | - |
dc.citation.endPage | 264 | - |
dc.identifier.bibliographicCitation | ANNALS OF HEMATOLOGY, Vol.99(2) : 255-264, 2020-02 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.